Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Niki BioSolutions, Inc. (NIKI)

Niki BioSolutions furnishes September 2026 investor presentation for H.C. Wainwright conference

Neutral Impact 1 of 5 other Written later

Niki BioSolutions filed its corporate presentation as Exhibit 99.1 to an 8-K for the H.C. Wainwright Global Investment Conference in September 2026. The deck recaps the all-stock merger with DiamiR Biosciences, which closed July 20, 2026, and outlines the company's Alzheimer's blood-testing plans, but it reports no new financial results. For shareholders, the filing is a routine update that restates strategy and timelines the company says cannot be guaranteed.

Key points

  • Presentation furnished as Exhibit 99.1 for the H.C. Wainwright Global Investment Conference, September 2026
  • Presentation states the DiamiR merger closed July 20, 2026, with DiamiR holding about 70% and Aptorum about 30% of the combined company
  • Company says its first pharma services customer contract is signed, with revenue generation expected from 3Q 2026
  • FDA has not approved CogniMIR as of September 2026; clinical validation is planned for 2027

The filing

CompanyNiki BioSolutions, Inc. (NIKI)
Form8-K, current report
Filed with the SECSep 14, 2026, 4:00 PM ET
Accession number0001213900-26-099695

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 14, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.